[Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Bevacizumab has been demonstrated to prolong survival in patients with metastatic colorectal cancer when used in combination with chemotherapy. We investigated the efficacy of chemotherapy administered in our general hospital for patients with metastatic colorectal cancer after the introduction of FOLFOX/FOLFIRI (+/-bevacizumab) therapy.


METHODS
The subjects in this study were 34 patients diagnosed with metastatic colorectal cancer, who received either FOLFIRI (+/- bevacizumab) or mFOLFOX6 (+/-bevacizumab) therapy in this hospital. The subjects were divided into a bevacizumab combination regimen group (those who received the regimen as first-line treatment), and a non-bevacizumab combination regimen group (those who did not receive the regimen as first-line treatment). Comparisons were made with regard to anticancer efficacy, progression-free survival time, and overall survival time.


RESULTS
Comparison between the bevacizumab combination regimen group and the non-bevacizumab combination regimen group, revealed no significant difference due to the small number of relevant patients. However, the former showed a slight advantage over the latter in terms of anti-cancer efficacy and progression-free survival time.


CONCLUSIONS
Bevacizumab is expected to contribute to the prolongation of survival in patients in our general hospital.
Hosoda
Kei
K
Dept. of Surgery, Ohtawara Red-Cross Hospital.
Aoki
Masahiko
M
Kido
Hiromu
H
Natsu
Kingen
K
Tamura
Hikaru
H
Kojima
Masao
M
Amemiya
Tetsu
T
Kamoshida
Takeshi
T
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006769:Hospitals, General; D006779:Hospitals, Public; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin